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Abstract 
Background: Infliximab (IFX), a TNF-α blocking chimeric monoclonal antibody, induces clinical response and 
mucosal healing in patients with inflammatory bowel disease (IBD). However, systemic administration of this agent 
causes unwanted side effects. Oral delivery of antibody therapeutics might be an effective treatment strategy for IBD 
compared to intravenous administration.
Results: All three carriers had a high encapsulation efficiency, narrow size distribution, and minimal systemic expo-
sure. There was a higher interaction between nanocomposite carriers and monocytes compared to lymphocytes in 
the PBMC of IBD patients. Orally administered nanocomposite carriers targeted to inflamed colitis minimized systemic 
exposure. All IFX delivery formulations with nanocomposite carriers had a significantly less colitis-induced body 
weight loss, colon shortening and histomorphological score, compared to the DSS-treated group. AC-IFX-L and EAC-
IFX-L groups showed significantly higher improvement of the disease activity index, compared to the DSS-treated 
group. In addition, AC-IFX-L and EAC-IFX-L alleviated pro-inflammatory cytokine expressions (Tnfa, Il1b, and Il17).
Conclusion: We present orally administered antibody delivery systems which improved efficacy in murine colitis 
while reducing systemic exposure. These oral delivery systems suggest a promising therapeutic approach for treating 
IBD.
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Background
Inflammatory bowel disease (IBD) is a chronic relaps-
ing inflammatory condition of the gastrointestinal tract. 
Cytokines are essential mediators of IBD pathophysiology 
and tumor necrosis factor (TNF)-α has a crucial func-
tion in the initiation and perpetuation of IBD [1]. TNF-α 
alters epithelial integrity, disrupts barrier function, and 
promotes the breakdown of intestinal homeostasis [2]. 
Moreover, the binding of TNF-α to the TNF receptor is 
associated with the prevention of apoptosis and prolon-
gation of pro-inflammatory T cell survival in IBD [3]. 
Increased blood monocyte recruitment into the gut of 
IBD patients generates macrophages that leads to the 
secretion of inflammatory cytokines such as TNF, IL-6, 
and IL-23 [4].
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Therapeutic monoclonal antibodies against TNF-α are 
used to treat IBD [5, 6]. These monoclonal antibodies 
have some advantages in terms of stability, bioavailability, 
and superior antigen targeting affinity. Infliximab (IFX) is 
a mouse/human chimeric monoclonal immunoglobulin 
G1 (IgG1) antibody against TNF-α. It directly neutralizes 
the biological activity of TNF-α. IFX is more effective at 
inducing clinical remission of IBD and mucosal healing 
than conventional drugs [7, 8]. However, IFX has infre-
quent but serious side effects such as infectious compli-
cations, autoimmune responses, and malignancy [9–11]. 
Furthermore, repeated intravenous administration of 
IFX is costly and associated with poor compliance [12]. 
Ideally, an anti-TNF antibody therapy for IBD would be 
delivered directly to the intestinal inflammatory sites, 
avoiding systemic exposure and immunosuppression.
Liposome is an attractive drug carrier; it has high bio-
compatibility and biodegradability, low toxicity, and 
non-immunogenic properties [13]. Liposomes are mainly 
composed of phospholipids, and the release rate depends 
on the number of phospholipid bilayers. Phospholipid 
barriers block the action of enzymes, acids, and free radi-
cals, and protect the cargo from breaking down until it 
reaches the target site and is released. Specific pH range-
triggered release and liposome encapsulation delays 
drug release specific to the gastrointestinal tract, which 
enhances therapeutic efficiency. Liposome-encapsulated 
IFX was observed to have therapeutic efficacy in autoim-
mune uveoretinitis [14]. In addition, liposomes provide 
better recovery of impaired epithelial barrier function 
than control in a dose-dependent manner [15]. Because 
ideal colon-specific delivery systems require the pre-
vention of premature drug release, the properties of the 
liposome surface coating material encapsulating the anti-
TNF-α agent are important because they affect the effi-
ciency of the delivery system. Ideal colon-specific delivery 
systems require the prevention of premature drug release 
before reaching the target site.
Aminoclay is a synthesized organoclay 3-aminopropyl 
functionalized magnesium phyllosilicate. Oral delivery 
systems designed with aminoclay complex enhance the 
bioavailability of a low solubility/high permeability drug 
[16]. Indeed, aminoclay is less cytotoxic and can reduce 
cargo dosages, while enhancing delivery efficiency and 
allowing for the loading of macromolecules [17]. How-
ever, the therapeutic effect or improvement of impaired 
barrier function in IBD via aminoclay-anti-TNF-α com-
plex has not yet been reported.
Eudragit (methacrylic acid copolymer) is a pH-sensitive 
coating polymer [18]. Eudragit with prednisolone was 
reported to efficiently degrade and deliver drugs only at 
colon-specific pH both in vivo and in vitro, thus mini-
mizing drug side effects [19]. In addition, Eudragit was 
able to deliver 5-aminosalicylic acids to the target site 
with minimal systemic absorption [20]. Furthermore, the 
Eudragit coating system has a higher mucosa-adhesive 
ability than control coating systems [21]. However, no 
studies of Eudragit encapsulating anti-TNF-α have been 
reported in vivo or in vitro.
Therefore, the aim of the current study was to evalu-
ate the effectiveness and safety of new oral colon-targeted 
IFX delivery systems using ternary nanocomposite carri-
ers in a murine colitis model.
Results
Characterization and gastrointestinal stability 
of nanocomposite carriers
Transmission electron microscopy images showed that 
bovine serum albumin-fluorescein isothiocyanate (BSA-
FITC) coated with liposome-coated BSA (BSA-lipo-
some), Aminoclay-liposome-coated BSA (AC-BSA-L), 
and Eudragit S100-liposome-coated BSA (EAC-BSA-L) 
were spherical and surrounded the inner aqueous core 
containing BSA-FITC (Fig. 1a). Particle size and zeta 
potential analysis using dynamic light scattering showed 
a gradual increase in particle sizes (360, 396, and 406 nm 
in BSA-L, AC-BSA-L, and EAC-BSA-L, respectively) 
and reversal of zeta potential values (− 79.9, + 12.6, 
and − 55.4 mV in BSA-L, AC-BSA-L, and EAC-BSA-
L, respectively) in the layer-by-layer coating. The net 
negative surface charge of BSA-L appeared to promote 
the alternating deposition of positively charged amino-
clays through electrostatic interactions. The positively 
charged surface of AC-BSA-L allowed the deposition of 
anionic Eudragit S100, resulting in layer-by-layer coated 
EAC-BSA-L. Entrapped BSA-FITC concentrations of 
nanocomposites were 768.6 ± 13.1 μg/mL (BSA-L), 
498.3 ± 85.0 μg/mL (AC-BSA-L), and 337.8 ± 15.3 μg/
mL (EAC-BSA-L). A gradual decrease in entrapped pro-
tein concentration by coating was caused by the leakage 
of entrapped proteins during the layering process. Encap-
sulation efficiency were 7.7 ± 0.1% (BSA-L), 5.0 ± 0.9% 
(AC-BSA-L), and 3.4 ± 0.2% (EAC-BSA-L). Nano-sized 
IFX-entrapped liposomes gradually increase in size (244, 
222, and 426 nm in liposome-coated IFX (IFX-L), Ami-
noclay-liposome-coated IFX (AC-IFX-L), and Eudragit 
S100-aminoclay-liposome-coated IFX (EAC-IFX-L), 
respectively) and zeta potential values were reversed 
(− 54.8, + 2.6, and − 31.5 mV in IFX-L, AC-IFX-L, and 
EAC-BSA-L, respectively) (Fig. 1b). Encapsulation effi-
ciency were 28.9 ± 2.4% (IFX-L), 14.8 ± 0.7% (AC-IFX-
L), and 6.9 ± 0.6% (EAC-IFX-L). Similar to the decrease 
in the concentration of nanocomposites with BSA, 
the entrapped concentrations of nanocomposites also 
decreased (2,888 ± 236, 1,480 ± 71, and 686 ± 63 μg/
mL in IFX-L, AC-IFX-L, and EAC-IFX-L, respectively). 
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Compared with BSA, IFX had a higher loading concen-
tration, which may be due to the difference between 
hydrophilic and hydrophobic aa domains. IFX contains 
more hydrophobic parts that are more compatible with 
phospholipid membranes than BSA, resulting in their 
entrapment at higher concentrations. Collectively, these 
observed structural properties confirmed the successful 
formation of the antibody drug delivery nanocomposites 
of liposomes, aminoclay, and Eudragit S100.
We next assessed the physical stability of BSA-entrap-
ping nanocomposite carriers under simulated gastro-
intestinal conditions by using the dialysis. The protein 
integrity profile of free BSA before and after exposure 
to simulated gastric fluid (SGF; 2 g NaCl/1L water, pH 
1.2, with or without 3.2 g/L pepsin) or simulated intes-
tinal fluid (SIF; 6.8 g  KH2PO4/1 L water, pH 6.8, with or 
without 10 g/L pancreatin) is shown in Additional file 1: 
Fig. S1. When free BSA solution was incubated in SGF 
without pepsin supplementation, no significant change 
in the BSA-corresponding protein band was observed, 
indicating the high protein stability of BSA under the 
experimental conditions (Additional file 1: Fig. S1a). 
The complete loss of the BSA band was observed after 
1-min incubation in SGF supplemented with pepsin, 
indicating a rapid protein degradation induced by enzy-
matic action (Additional file 1: Fig. S1b). In SIF supple-
mented with pancreatin, protein degradation was slower 
than control, but occurred in a time-dependent manner 
(Additional file 1: Fig. S1c). The decrease in the protein 
band of the BSA obtained from nanocomposite carri-
ers (BSA-L, AC-BSA-L, and EAC-BSA-L) was much less 
and slower in both SGF and SIF (supplemented with 
pepsin or pancreatin), compared to free BSA solution 
(Fig. S1d, e).
Particle size changes and protein release profiles from 
the three nanocomposite carriers were also examined 
in PBS, SGF, or SIF (Fig. 1c). Eudragit S-100 is a pH-
sensitive formulation that decomposes above pH 7, 
and because Eudragit-coating does not peel off in PBS 
and SIF, the size of the nanocomposite carriers was 
unchanged. All of the tested nano-formulations were 
observed to have delayed and reduced drug release 
(Fig. 1d). In particular, EAC-BSA-L showed minimal 
drug release in SIF for 2 h, suggesting its superior ability 
to retard premature release of the protein drug. EAC-
BSA- L increased in size as soon as it was added to SGF. 
However, because there was no change in size until 8 h 
and there was no change of protein structure in circular 
dichroism data, EAC-BSA-L exists as a weak aggregate 
between particles under acidic conditions, but there 
was no change in the structure of the nanocomposite 
carriers. In PBS incubation, the spectra of free BSA 
and the other three nanocomposite-encapsulated BSAs 
were different (Fig. 1e). This may be due to the separa-
tion of the liposomes by adding SDS just before the cir-
cular dichroism measurement to isolate the BSA inside 
the liposome. Collectively, the α-helix structure of free 
BSA was broken under SGF (pepsin +) for 1 h. Whereas 
the structure of BSA with nanocomposite carriers was 
much better maintained than free BSA group, espe-
cially to BSA encapsulated in EAC-BSA-L remained 
nearly intact. These results indicate the successful fab-
rication of drug delivery nanocomposite carriers with 
the ability to safely and slowly release encapsulated 
cargo under gastric and intestinal conditions.
Targeting ability of nanocomposite carriers
To confirm targeting ability, we performed an in vivo 
drug targeting study using Cy7-labeled nanocompos-
ite carriers in mice with dextran sulfate sodium (DSS)-
induced colitis fed a purified diet AIN-76A (Table S1). 
DSS colitis model was used for simplicity and many 
similarities to IBD, especially human ulcerative colitis 
[22]. At 7 h post oral administration of the Cy7 labeled 
delivery carriers, fluorescence imaging showed stronger 
Cy7 fluorescence signal in the colon and a significant 
but weaker Cy7 fluorescence signal in the small intes-
tine (Fig. 2a, b). In the cecum and colon without colitis, 
EAC-L group exhibited higher fluorescence signals. In 
contrast, other organs (heart, lung, liver, spleen, pan-
creas, and kidney) did not show significant Cy7 fluores-
cence signals (Fig. 2c). The average radiant efficiency of 
all nanocomposite carriers in the inflamed colon was 
increased. The AC-L treated mice with the inflamed 
colon had higher values than DSS only group and mice 
treated with EAC-L without colitis had higher values 
than control groups (Fig. 2d). These results of the bio-
distribution study using Cy-7 indicate no significant 
systemic exposure of nanocomposite carriers when 
orally administered to target the inflamed colon.
Nanocomposite carriers enhance the anti‑inflammatory 
capacity of intestinal macrophages
Peripheral blood monocytes and lymphocyte can 
migrate and infiltrate to the inflammatory gastrointes-
tinal mucosa [23, 24]. The potent anti-inflammatory 
capacity of T cells and monocytes have a crucial func-
tion in colitis. Dysregulation of CD4 T helper cells and 
their signature cytokines can contribute to IBD patho-
genesis [25]. TNF-α secretion is significantly increased 
by inflamed lamina propria monocytes in IBD patients, 
and the clinical severity of IBD and serum TNF-α 
level are correlated [26, 27]. To evaluate the effects 
of nanocomposite carriers (L-FITC, AC-L-FITC, and 
EAC-L-FITC) on lymphocytes  (CD3+CD4+ cells) and 
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FITC-BSA
liposome AC-L EAC-L
size (nm) 360 19 396 37 406 23
zeta potential (mV) -79.9 0.6 +12.6 0.5 -55.4 0.2
Encapsulation concentration 
(μg/mL) 768.6 13.1 498.3 85.0 337.8 15.3





size (nm) 244 22 222 14 426 16
Zeta potential (mV) -54.8 1.0 +2.6 0.2 -31.5 1.2
Encapsulation concentration 
(μg/mL) 2888.5 236.2 1479.5 71.5 686 63
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Fig. 1 Characteristics of nanoparticles. a Transmission electron microscopy (TEM) images of fluorescein isothiocyanate (FITC)-bovine serum 
albumin (BSA) with nanocomposite carriers (liposome, aminoclay-coated, and Eudragit S100-clay-coated). Scale bar of single nanocomposite 
carrier represents 50 nm. The scale bar of BSA-L and EAC-BSA-L in the TEM images of lower magnification is 200 nm, and the scale bar of AC-BSA-L 
in the TEM images of lower magnification is 500 nm. The zeta potential is the mean ± SD of two independent experiments (n = 2), and the size 
and captured concentration data are the mean ± SD of three independent experiments (n = 2). b TEM images of Eudragit S100-aminoclay-coated 
liposomes entrapped with infliximab (IFX). Scale bar of single nanocomposite represents 100 nm. The scale bar of the TEM images of 
lower magnification is 200 nm. Size, zeta potential, and concentration of IFX encapsulated by nanocomposites were measured. AC-BSA-L, 
aminoclay-liposome-coated BSA; BSA, bovine serum albumin; BSA-L, liposome-coated BSA; EAC-IFX-L, Eudragit S100-liposome-coated IFX; 
Eudragit S100-aminoclay-liposome-coated IFX; FITC-BSA, BSA-fluorescein isothiocyanate conjugate. c Time-dependent size changes of liposome, 
clay-liposome, and E100-clay-liposome incubated in PBS, SIF, or SGF at 37 °C. d Time-dependent fluorescein isothiocyanate-bovine serum albumin 
(FITC-BSA) release profile from liposomes incubated in phosphate-buffered saline (PBS) or simulated intestinal fluid (SIF, without pancreatin) at 37 °C. 
e Circular dichroism analysis of the BSA stability in the nanocomposites
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monocytes  (CD11b+ cells) in PBMCs of IBD patients, 
we observed a subset of  CD3+CD4+ T cells and  CD11b+ 
monocytes (Additional file 1: Fig. S2a). The mean fluo-
rescence intensity (MFI) values of nanocomposite car-
riers in lymphocytes were between 1000 and 3000, and 
those of nanocomposite carriers in monocytes were 
between 3000 and 15,000. Lymphocytes of patients 
with ulcerative colitis had significantly higher MFI val-
ues in the all nanocomposite carrier groups compared 
to the BSA-FITC group, whereas monocytes in ulcera-
tive colitis patients did not differ significantly from 
those of BSA-FITC group (Additional file 1: Fig. S2b). 
The EAC-L-FITC group had significantly higher MFI 
values in the lymphocytes and monocytes of patients 
with Crohn’s disease compared to the BSA-FITC group. 
AC-L-FITC group had significantly a higher MFI value 
in lymphocytes of Crohn’s disease patients than BSA-
FITC group, but there was no difference in monocytes. 
These results suggest that nanocomposite carriers may 
have a higher absorption into monocytes than lympho-
cytes, and that absorption into lymphocytes show a sig-
nificant difference between carriers.
IFX‑L, AC‑IFX‑L, and EAC‑IFX‑L delivered IFX to targeted 
inflamed colon and resulted in therapeutic effects
We examined the therapeutic effects of L, AC-L, EAC-
L, PO-IFX, and IP-IFX (10 mg/kg) in mice with DSS-
induced colitis (Additional file 1: Fig. S3a). Our results 
showed that liposome-treated mice had a significantly 
less colitis-induced body weight loss and colon short-
ening (Additional file 1: Fig. S3b, c). In addition, mice 
treated via intraperitoneal injection of IFX had a sig-
nificant reduction of colon shortening (Additional file 1: 
Fig. S3c). These results were further supported by DAI 
findings (Additional file 1: Fig. S3d). In the PAS-stained 
colon tissues, mice treated with liposomes (L group) or 
IFX via intraperitoneal injection (IP-IFX group) had less 
colon tissue damage and inflammatory cell infiltration 
than those treated with other nanocomposite carriers 
or control group (Additional file 1: Fig. S3e). Histomor-
phological scores were significantly lower in in L and IP-
IFX groups compared to the DSS inflammation group, 
whereas goblet cell scores were not significantly differ-
ent between the treatment groups. These results might 
suggest that drug delivery via liposome encapsulation is 
superior to other nanocomposite carriers in terms of its 
anti-inflammatory effects.
To test the therapeutic effects of nanocomposite 
carriers loaded with IFX, mice were orally adminis-
trated PBS, IFX-L, AC-IFX-L, EAC-IFX-L, or IFX daily 
(10 mg/kg, PO) from day 0 to day 8 (total 9 days). Coli-
tis was induced by administering 1.5% DSS through 
drinking water for 7 days (Fig. 3a). IFX-L, AC-IFX-L, 
and EAC-IFX-L groups resulted in significantly less 
weight change, compared to the DSS-treated group 
(Fig. 3b). All IFX delivery formulations with nanocom-
posite carriers had a significantly greater therapeutic 
effect in terms of colon length reduction and histo-
pathological inflammatory cell infiltration, compared 
to the DSS-treated group (Fig. 3c, e). There was no 
significant difference in colon shortening between the 
nanocomposite carriers themselves and the IFX encap-
sulated by nanocomposite carriers. There was a sig-
nificantly higher improvement of DAI in the AC-IFX-L 
and EAC-IFX-L groups, compared to the DSS-treated 
group (Fig. 3d). Interestingly, EAC-IFX-L showed lower 
DAI value than EAC-L. All IFX delivery formulations 
with nanocomposite carriers showed significantly lower 
histomorphological scores than the DSS-treated group. 
The IFX-L group showed a higher goblet cell score than 
the DSS-treated group. AC-IFX-L group showed lower 
histomorphological scores and higher goblet cell scores 
than AC-L group. These results suggest that the conju-
gation of IFX to nanocomposite carriers preserves IFX 
function which successfully targets the colitis site.
Anti‑inflammatory effects of nanocomposite carriers 
loaded with IFX
We used western blotting to investigate the effects of IFX 
delivery formulations on the protein expression of TNF-α 
and IL-1β. Induction of inflammation by DSS increased 
the expression of TNF-α and IL-1β, whereas protein 
expression in the EAC-IFX-L group was significantly 
decreased (Fig. 4a). The expression of TNF-α in the AC-
IFX-L group was also significantly decreased, compared 
to the DSS only group.
As an indicator of therapeutic effect of the IFX deliv-
ery formulation against inflammation, TNF-α expression 
in serum extracted from mice was measured by ELISA. 
In the all IFX delivery formulations with nanocomposite 
carrier groups, the expression levels of TNF-α were sig-
nificantly decreased compared to the DSS-treated con-
trol group (Fig. 4b).
Inflammation-related factors (Il1b, Tnfa, Il6, Il17, 
and Inos) were analyzed at the mRNA level in the DSS 
colitis colon after receiving IFX delivery formulation 
(Fig. 4c). The IFX-L group exhibited significantly lower 
level of Tnfa and Il17 compared to the DSS-treated con-
trol group. Interestingly, the levels of Il1b and Il17, as 
well as Tnfa, were reduced in the AC-IFX-L and EAC-
IFX-L groups. All drug delivery formulations showed 
no significant decrease in Inos and Il6 compared to the 
DSS-treated group. However, there was a larger fold 
change in mRNA levels of inflammation-related factors 
in the direct oral administration of IFX group without 
carriers than via drug delivery formulations, but this was 
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no statistically significant difference (Additional file 1: 
Fig. S4). Collectively, these results suggest that the three 
drug delivery formulations with entrapped IFX success-
fully targeted Tnfa in the inflamed colon and had an 
anti-inflammatory effect in a DSS-induced colitis model.
Discussion
Colon-targeted oral drug delivery systems are quite an 
attractive therapeutic strategy for the treatment of dis-
eases affecting the colon, such as IBD [28, 29]. An ideal 
colon-specific delivery system maintains the maximum 
target-specific concentration of an entrapped drug, while 
minimizing systemic exposure by preventing premature 
drug release. The colon, a suitable delivery target site for 
proteinaceous drugs, has relatively limited proteolytic 
activity compared to other parts of the gastrointestinal 
tract. The residence time of drugs in the colon is also 
relatively longer than that of other sites [30, 31]. In this 
regard, the properties of surface coating materials and 
their interactions with liposomes are important deter-
minants of the effects of liposome drug carriers target-
ing the colon. The efficiency of orally administered drugs 
delivered to the colon is improved by the polymer coat-
ing liposome formulation via pH-dependent release and 
a
b
DSS+Veh DSS+Cy7_L DSS+Cy7_AC-L DSS+Cy7_EAC-L
Vehicle (Veh) Veh+Cy7_L Veh+Cy7_AC-L Veh+Cy7_EAC-L
DSS+Veh DSS+Cy7_L DSS+Cy7_AC-L DSS+Cy7_EAC-L
Veh Veh+Cy7_L Veh+Cy7_AC-L Veh+Cy7_EAC-L
Small intestine
Colon






Fig. 2 Drug delivery formulations in vivo are effectively delivered to inflamed colon and do not have a systemic effect. Images were obtained 7 h 
after oral administration of Cy7-labeled delivery carriers using an in vivo imaging system (IVIS). a Fluorescence of Cy7 measured in the inflamed 
colon was observed in all drug delivery carrier groups. Arrows indicate strong fluorescence signals at the site of inflammation. b In inflamed small 
intestine, the AC-L group and EAC-L group were measured for fluorescence of Cy7. c Fluorescence images of Cy7 in a multi-well format obtained 
from organs (heart, lung, liver, spleen, pancreas, and kidney). d Average radiant efficiency of drug delivery formulations distributed in inflamed 
intestine in comparison to normal conditions. Data representative of eight independent groups with n = 3 mice/group (Vehicle group), n = 1 
mice/group (Vehicle with Cy7 labeled L), n = 1 mice/group (Vehicle with Cy7 labeled AC-L), n = 3 mice/group (Vehicle with Cy7 labeled EAC-L), 
n = 2 mice/group (DSS colitis with vehicle), n = 2 mice/group (DSS colitis with Cy7 labeled L), n = 2 mice/group (DSS coltis with Cy7 labeled AC-L), 
n = 2 mice/group (DSS colitis with Cy7 labeled EAC-L. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Statistical 
significance was assessed using Student’s t-test (d) and one-way ANOVA followed by Dunnett post-test. Control, treated with vehicle; DSS+Cy7_
AC-L, DSS colitis with aminoclay-liposome-coated Cy7; DSS+Cy7_EAC-L, DSS colitis with Eudragit S100-liposome-coated Cy7; DSS+Cy7_L, DSS 
colitis with liposome-coated Cy7
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mucosa-adhesive properties. In addition, phosphatidyl-
choline, a major component of the gastrointestinal mem-
brane and liposome, reduces the inflammatory response 
and induces remission in patients with ulcerative colitis 
[32]. Aminoclay is an excellent material for improving 
the bioavailability of poorly water-soluble drugs. The 
drug-clay complexes can regulate drug release properties 
by interacting with negatively charged drug molecules in 
water. Indeed, various delivery systems have been devel-
oped using Eudragit-coated liposome or aminoclay as 
efficient and versatile biocompatible carriers [33, 34]. The 
charges of AC-L are made positive by the amino groups 
(-NH3) of aminoclay and the charges of the anionic poly-
mer nanoparticles of EAC-L are negative because of the 
carbonyl groups on the polymeric chain extremities. 
Overall, the results of the current study showed that 
nanocomposite carriers can serve as efficient oral delivery 
carriers in the treatment of IBD.
In this study, the degradation of nanocomposites 
entrapped with BSA was not significant in SGF and SIF, 
and the release rate of BSA in PBS and SIF was lower 
than that of free BSA. Normal pH ranges from 5.9 in 
the proximal colon to 6.1 in the distal colon, However, 
colon pH values in IBD patients vary significantly from 
pH 4.8 to 7.3 [35, 36]. Because bile salts and digestive 
enzymes (pancreatin) have a synergistic effect on the 
breakdown of liposome membranes in SIF, drug release 
rates increase in SIF compared to SGF [28, 37]. How-
ever, in this study, the difference in diameter change 







DSS+AC-IFX-L DSS+EAC IFX-L DSS+IFX (PO)
Control
Fig. 3 Therapeutic effects of drug delivery formulations in mice with dextran sulfate sodium-induced colitis. a The methods for DSS-induced 
colitis and oral delivery carriers with infliximab (IFX) administration, control (n = 4), DSS only (n = 10), IFX-L group (n = 6), AC-IFX-L (n = 6), EAC-IFX-L 
(n = 10), PO-IFX (n = 8). b Body weight changes of each group in DSS-induced colitis mouse model. c Colon length; values are represented as length 
(cm). d The clinical activity scores in the control group and treatment groups measured using the disease activity index (DAI). e Histopathologic 
features of nanocomposite carriers and IFX delivery formulations on the DSS-induced colitis mouse model, via PAS staining. Arrows indicate 
inflammatory cells in the lamina propria. Scale bar: 20 μm. Histomorphological scores and Goblet cell scores. Data are expressed as mean ± SD. 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Statistical significance was assessed using Student’s t-test (d) and one-way ANOVA followed by 
Dunnett post-test
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less susceptible to pepsin alone and stable to pancrea-
tin at neutral pH without bile salts [38]. The reason 
that results of the current study differ from previous 
studies may be because we did not mix bile salts with 
digestive enzymes that could break the integrity of 
liposome by solubilizing the membrane and forming 
temporary pores. However, the current study showed 
that the nanocomposite carriers are stable even at dif-
ferent pH changes, such as in the stomach or small 
intestine, and can reach the colon by maintaining sta-
ble drug concentrations for a long time. The stability of 
BSA was analyzed by circular dichroism spectroscopy 
which indicated that the α-helix structure of free BSA 
was broken after 1 h under SGF (pepsin +). However, 
the BSA in nanocomposite carriers retained a much 
better structure than free BSA, especially in EAC-L was 
included.
IBD patients are characterized by altered expression 
of tight junction proteins and loss of barrier integrity 
[39, 40]. In addition, TNF-α, a pathological cytokine, 
increases epithelial permeability through changes in tight 
junction function and structure. Since IFX is adminis-
tered intravenously as a monoclonal antibody, TNF is 
systemically antagonistic.
This method of administration is associated with sev-
eral side effects and leads to the formation of antibod-
ies to infliximab associated with loss of response to IFX 
and infusion responses [9–11, 41]. Daily oral treatment 
with IFX minimizes the decrease of TNF concentra-


















Fig. 4 Anti-inflammatory effects of nanocomposite carriers loaded with IFX. a Western blot analysis of protein expression of TNF-α and IL-1β in 
drug delivery formulations with IFX and their effects on the production and regulation of inflammation-related factors. The ratios to beta-actin 
to standardize cytokine protein expression in mice with DSS-induced colitis compared to control mice. b Expression of TNF-α in plasma of 
mice with DSS-induced colitis using ELISA. c Expression of inflammation-related cytokines mRNA levels in the colon of mice with colitis treated 
by IFX using drug delivery formulations. Gene expression were evaluated by quantitative RT-PCR and relative expression was reported as fold 
change compared to the control by normalizing transcription level to β-actin. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; 
****p <0.0001. Statistical significance was assessed using Student’s t-test (C-I) and one-way ANOVA followed by Dunnett post-test. AC-IFX-L, 
aminoclay-liposome-coated IFX; EAC-IFX-L, Eudragit S100-aminoclay-liposome-coated IFX; IFX, Infliximab; IFX-L, liposome-coated IFX; control, 
treated with vehicle
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can continuously expose the relatively high concentra-
tions of IFX to the confined targeted area of treatment 
[42, 43]. In this study, we orally administered IFX target-
ing the colon using liposomes, aminoclay, and Eudragit 
S100-based nanocomposite carriers. In previous studies, 
in vivo image analysis by confocal microscopy confirmed 
the effective intracellular distribution of fluorescently 
labeled nanocomposite carriers in the colon [44, 45]. 
The expression of each macrophage marker gene and the 
accumulation of liposomes showed a significant positive 
correlation, and liposomes enhanced the accumulation 
of drug candidates through macrophages in damaged 
colon tissues [46]. In addition, the fluorescence intensity 
of fluorescence-labeled liposomes is closely related to the 
expression levels of the macrophage marker. This indi-
cates that the absorption mechanism of the liposomes is 
related to the phagocytic property of macrophages [46]. 
Furthermore, a previous study of nanocomposite carriers 
using aminoclay and Eudragit in LPS-stimulated RAW 
264.7 cells, found no toxicity to macrophages [45]. The 
results of these publications, taken together with those 
of the current study, indicate that these nanocomposites 
may be good candidates as carriers for oral drug delivery.
Since Eudragit degrades below pH 6.8 and the gastro-
intestinal tract in mice is shorter than that of humans, 
the therapeutic effects of EAC-L and EAC-IFX-L require 
further study. Importantly, our work provides additional 
insight into the development of orally administered 
nanocomposite carriers for the treatment of colitis. In 
addition, our method of coating IFX has already proven 
to be an effective approach in treating IBD and has the 
potential to be used in personalized medicine to pro-
vide a tailored oral delivery carrier because it reaches the 
colon and targets macrophages with unique biocompat-
ibility and biodegradability.
The increased secretion of TNF-α and IL1β in the 
colonic lamina propria has an important function in the 
development of IBD. Patients with ulcerative colitis have 
higher baseline levels of IL1β and TNF-α than in patients 
with Crohn’s disease [47]. IFX treatment increases the 
apoptosis of T lymphocytes in the intestinal mucosa 
[48]. The expression of Il17 is increased in the intestinal 
mucosa and serum of IBD patients [49]. The reduction of 
Il17 expression in the intestinal mucosa of IBD patients is 
closely associated with endoscopic response and mucosal 
healing after IFX treatment [50]. Our results indicate that 
drug delivery formulations significantly increased MFI 
values for lymphocytes in patients with ulcerative colitis, 
while the mRNA expression of Tnfa, Il1b, and Il17 was 
significantly decreased. Il1b and Il17, which are involved 
in the pathogenesis of IBD due to innate lymphoid cells 
and  CD4+ Th17 cells, were significantly decreased in 
the EAC-IFX-L group [51, 52]. Therefore, although our 
EAC-L data suggest that it is selectively taken by mac-
rophages to improve DSS-induced mouse colitis, fur-
ther studies on the molecular mechanisms regulating 
macrophage function are necessary. Our results indicate 
that carriers coated with liposomes alone and aminoclay-
coated liposomes also contributed to anti-inflammatory 
responses. Further studies on the regulation of inflam-
matory cytokines by the carriers themselves are required 
to confirm their anti-inflammatory effects and those of 
liposomes.
Conclusion
All three nanocomposite carriers loaded with IFX were 
prepared with narrow size distribution and high encap-
sulation efficiency. Theses nanocomposite carriers loaded 
with IFX provide a colon-specific anti-inflammatory 
effect without adversely affecting systemic homeosta-
sis. Oral drug delivery by EAC-L may be a novel means 
of transporting large molecule drugs to the intestines in 
a non-cytotoxic way, to stimulate  CD4+ T cells as well 
as macrophages. Furthermore, the unique propensity of 
EAC-L enhances anti-inflammatory responses of intes-
tinal macrophages and provides attractive strategies 
for preventing or treating autoimmune diseases. All the 
three nanocomposite carriers loaded with IFX had better 
colitis improvement than the control group. In addition, 
IFX treatment by AC-IFX-L and EAC-IFX-L-based nano-
composites not only showed a significant anti-inflamma-
tory effect, but also remarkably decreased TNF-α level in 
a DSS-induced mouse colitis model. This suggests that 
these oral anti-TNF delivery systems be a promising ther-





sodium salt (DMPG) were purchased from Avanti Polar 
Lipid Inc. (Alabaster, AL, USA). Cholesterol (Chol), 
α-tocopherol, bovine serum albumin (BSA) fluorescein 
isothiocyanate conjugate (FITC-BSA), ammonium per-
sulfate, pepsin, pancreatin, and  Remicade® (IFX) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Cy™7 Mono NHS Ester was purchased from GE Health-
care (Little Chalfont, Buckinghamshire, UK). BCA 
Protein Assay Kit and PageRuler Prestained Protein 
Ladders were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). Sodium dodecyl sulfate (SDS) was 
purchased from Kracker Scientific (NY, USA). Coomas-
sie-brilliant blue R-250 staining solution, 30% acryla-
mide/Bis solution (29:1), TEMED, 4 × Laemmli sample 
buffer, 1.5 M Tris–HCl buffer and 0.5 M Tris–HCl buffer 
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were purchased from Bio-Rad Laboratories (Hercu-
les, CA, USA.). Magnesium chloride hexahydrate (98%) 
and other inorganic salts were purchased from Junsei 
Chemical Co. (Tokyo, Japan).  Eudragit® S100 was kindly 
donated by Evonik Korea (Seoul, Korea).
Preparation of liposomes
DMPC, Chol, DMPG, and α-tocopherol were mixed at a 
molar ratio of 26:10:2:2 in tertiary butyl alcohol. The mix-
tures were frozen at − 80 °C overnight followed by freeze-
drying (EYELA FDU-1200, Tokyo, Japan) for 24 h. The 
lipid cakes (total 40 μmol of lipid mixture) obtained were 
hydrated with 1 mL of IFX solution, which was obtained 
by dissolving Remicade powder in distilled water (10 mg/
mL), or FITC-BSA solution in phosphate-buffered saline 
(pH 7.4). The hydrated liposome dispersions were vor-
texed and sonicated for 1 h at 24 °C of DMPC by using 
an ultrasonic cleaning bath  (Branson®, 3510-DTH Ultra-
sonic Cleaner, Danbury, CT, USA). To obtain a liposomal 
dispersion with increased homogeneity and reduced par-
ticle size, additional sonication was carried out by using 
a cell disruptor  (Bioruptor®, UCD-200T, Cosmo Bio Co., 
Tokyo, Japan) as previously described [53]. Liposome dis-
persions were then subjected to freeze-thawing for five 
cycles of 5 min incubation at − 180 °C and 15 min incu-
bation at 37 °C to improve the protein encapsulation. To 
remove non-encapsulated proteins, liposomes were col-
lected by centrifugation at 43,000×g for 1 h at 4 °C. The 
resulting pellets were re-suspended in the original vol-
ume of phosphate-buffered saline (PBS). The prepared 
liposomes were stored at 4 °C until use.
Coating of liposomes
The 3-aminopropyl-functionalized magnesium phyllosili-
cate (aminoclay) was synthesized by following a method 
described previously [45]. Before coating, the bulk amino-
clay powder was dispersed in water, followed by ultrason-
ication for 10 min, for the exfoliation of the aminoclay. 
Aminoclay-coated liposomes (AC-L) were obtained by 
spontaneous assembly of positively charged aminoclay 
on negatively charged liposomal surfaces. Briefly, equal 
volumes of liposome dispersions pre-diluted with dis-
tilled water to give a lipid concentration at 10 mg/mL 
were added drop-wise to exfoliated aminoclay dispersion 
(10 mg/mL) to give a lipid/clay weight ratio of 1:1. The 
mixture was incubated at 25 °C for 30 min with stirring 
and then centrifuged at 15,000×g for 7 min at 4 °C. The 
resulting aminoclay-liposome pellets were re-suspended 
in 1 mL of PBS.
For further coating of clay-liposomes with Eudragit 
S-100, an equal volume of clay-liposome dispersions pre-
diluted to a concentration of 2.5 mg lipid per mL was 
added drop-wise to 0.1% Eudragit S100 solution in PBS. 
The mixture was incubated at 4 °C for 30 min with stir-
ring and then centrifuged at 15,000×g for 7 min at 4 °C. 
The resultant Eudragit S100-coated aminoclay-liposome 
(EAC-L) pellets were re-dispersed in the original volume 
of PBS.
Physicochemical characterization of liposomes
The mean particle size and polydispersity index of nano-
composite carriers were measured by dynamic light 
scattering using a fiber-optics particle analyzer (FPAR-
1000, Otsuka Electronics, Osaka, Japan) as described in 
our earlier studies [15]. Particle size analysis data were 
assessed using the CONTIN program provided by the 
manufacturer. Zeta potential (the electrical potential at 
the shear plane of the nanoparticle) was measured using 
a Zetasizer Nano ZSP (Malvern, UK). Samples were 
diluted 50-fold with deionized water before measuring to 
reach the analytical measurement range. Default instru-
ment settings and automatic analysis were used for all 
measurements. Each measurement was carried out in 
duplicate.
The diameter and morphology of liposomes were 
imaged by negative-stain transmission electron micros-
copy. Liposome samples were 50-fold diluted with PBS 
solution and dropped on a 200-mesh copper grid coated 
with carbon and negatively stained with 2% uranyl ace-
tate for 1 min. Excess stain was removed and the samples 
were allowed to air-dry completely. Dried samples were 
examined using a Tecnai G2 Spirit (FEI Company, Hills-
boro, OR, USA) operating at 120 keV.
The encapsulated concentration of IFX and FITC-BSA 
were determined by BCA protein assay or by measur-
ing the fluorescence of FITC (excitation 490 nm, emis-
sion 525 nm) with a fluorescence spectrometer (FS-2, 
Scinco Ltd., Seoul, Korea) after disrupting the liposome 
dispersions with an equal volume of 10% SDS (fluores-
cence assay) or ethanol (BCA assay). Standard curves 
pre-constructed with serial dilutions of FITC-BSA with 
ethanol were used to convert fluorescence to FITC-BSA 
concentration. The stability of BSA in the nanocomposite 
carriers was investigated using circular dichroism spec-
troscopy. Gastrointestinal stability of liposomes and pro-




Eight-week-old C57BL/6 mice were kept under standard 
conditions at 21–22 °C under 12 h light/dark cycle and 
allowed to acclimate for a week before starting the exper-
iment. Body weight and physical activity were monitored 
daily.
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Distribution of nanocomposite carriers in dextran sulfate 
sodium colitis mice
To assess the biodistribution of nanocomposite carriers 
after oral administration, Cyanine-7 (Cy7)-labeled nano-
composite carriers were prepared. Briefly, two μg of Cy7 
was dissolved with 40 μmol of DMPC:Chol:DMPG:α-
tocopherol (26:10:2:2) mixture in tertiary butyl alco-
hol. The liposomes were prepared from the mixture as 
described above, except that the un-entrapped Cy7 was 
separated from the liposomes by dialysis. Each lipo-
some dispersion was adjusted to 0.44 μg/mL before oral 
administration.
Colitis was induced in mice by oral administration 
of 1.5% (wt/vol) DSS (36-50 KD molecular weight, MP 
Biomedicals, Solon, OH, USA) for 5 days in drinking 
water [54]. After fasting for 12 h, Cy7.0-L, Cy7-AC-L, 
and Cy7-EAC-L were orally administered to mice with 
DSS-induced colitis at a dose of 20 mg/kg in a volume 
of 100 μL PBS. Control mice maintained normal drink-
ing water for 5 days and then Cy7.0-EAC-L was admin-
istrated orally at the same dose. Mice were sacrificed 
7 h after administration of Cy7.0-labeled nanocompos-
ite carriers. Cy7.0-labeled nanocomposite carriers were 
visualized (Cy7: excitation 750 nm, emission 773 nm) 
and analyzed by using an in vivo image analyzer (Cali-
per IVIS Lumina II, Caliper Life Science, USA).
DSS‑induced colitis and therapeutic effect 
of nanocomposite carriers
To test the therapeutic effect of nanocomposite carri-
ers, colitis was induced in mice by administering 1.5% 
DSS in their drinking water for 7 days [22, 55]. Mice 
were randomly divided into five different groups: DSS 
only (DSS-treated control group), DSS-treated with L 
(L group), DSS-treated with AC-L (AC-L group), DSS-
treated with EAC-L (EAC-L group), DSS-treated with 
intraperitoneal IFX (IP-IFX group), and DSS-treated 
with per-oral IFX (PO-IFX group). Mice in the L, AC-L, 
and EAC-L groups were orally administered nano-
composite carriers for 9 days, from day 0. The dose of 
nanocomposite carriers (10 mg/kg for all groups) was 
predetermined to have an optimal therapeutic effect. 
Mice received 4 mg/kg of IFX in 200 μL PBS daily by 
oral or intraperitoneal administration for nine consecu-
tive days. The dose of IFX was determined to have an 
optimal therapeutic effect based on existing studies [56, 
57]. Drinking water was replaced with pure water and 
maintained for 2 days. Changes in body weight, stool 
consistency, and presence of blood in the stool or at the 
anus were measured daily throughout the study period. 
Mice were sacrificed at day 12; spleen and colons were 
collected to assess the therapeutic efficacy of the nano-
composite carriers. Disease activity index (DAI) was 
evaluated using the summed score of three factors 
(weight loss, stool consistency, and bleeding) [58].
DSS‑induced colitis and the therapeutic effect 
of nanocomposite carriers‑IFX conjugates
To test the therapeutic effect of nanocomposite car-
riers loaded with IFX, colitis was induced in mice via 
the addition of 1.5% DSS to drinking water for 7 days. 
Drinking water was then replaced with pure water for 
4 days. All mice were sacrificed on day 11. Mice were 
orally administered, 200 μL PBS, IFX-L (10 mg/kg), 
AC-IFX-L (10 mg/kg), EAC-IFX-L (10 mg/kg) or PO-
IFX (10 mg/kg), once daily, from day 0 to day 8 (total 
9 days). The dose of nanocomposite carriers and IFX 
was predetermined to have an optimal therapeu-
tic effect [56, 57]. Flow cytometry, qRT-PCR, analy-
sis of TNF-α by enzyme-linked immunosorbent assay 
(ELISA), and western blotting are described in the Sup-
plementary Information.
Histology
Colon tissues were fixed in 10% neutral formalin and 
then embedded in paraffin. Tissues were stained by 
hematoxylin and eosin and periodic acid Schiff (PAS) 
staining. The severity of colitis was scored as described 
previously [22]. Goblet cell staining was scored from 
0 to 3 (3, minimal, < 20%; 2, mild, 21–35%; 1, moderate, 
36–50%; 0, marked, > 50%).
Goblet cell counting
Colonic tissue sections were processed with PAS stain-
ing. Stained goblet cells were counted per crypt. Maxi-
mum 52 and minimum 20 fully conserved crypts on 
each section were examined, and the average numbers 
were marked as a representative goblet cell count of each 
section.
Statistical analysis
The data were reported as mean and standard deviation. 
Comparison among groups was done by performing Stu-
dent’s t-tests or one-way analysis of variance (ANOVA) 
followed by Dunnett post-test using GraphPad Prism 
software (La Jolla, CA, USA). Results with a p value < 0.05 
were reported as statistically significant.
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